Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

LXRX holding history

Lexicon Pharmaceuticals, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

LXRX overviewAll 13F holders of LXRXFull Q2 2026 holdings

Shares (Q2 2026)
684,713
Value
$1.64M
% of portfolio
<0.1%
Quarters held
22
Since Q1 2021
Holdings of LXRX by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 2026684,713$1.64M<0.1%−1,798,469−72.4%ReducedHolders
Q1 20262,483,182$3.87M<0.1%−524,055−17.4%ReducedHolders
Q4 20253,007,237$3.46M<0.1%+2,654,315+752.1%AddedHolders
Q3 2025352,922$476.4K<0.1%−47,810−11.9%ReducedHolders
Q2 2025400,732$379.1K<0.1%−1,694,608−80.9%ReducedHolders
Q1 20252,095,340$966.0K<0.1%+1,409,223+205.4%AddedHolders
Q4 2024686,117$507.0K<0.1%+546,125+390.1%AddedHolders
Q3 2024139,992$219.8K<0.1%−21,121−13.1%ReducedHolders
Q2 2024161,113$270.7K<0.1%−5,848−3.5%ReducedHolders
Q1 2024166,961$400.7K<0.1%−2,655−1.6%ReducedHolders
Q4 2023169,616$259.5K<0.1%+44,254+35.3%AddedHolders
Q3 2023125,362$136.6K<0.1%+27,799+28.5%AddedHolders
Q2 202397,563$223.4K<0.1%−41,163−29.7%ReducedHolders
Q1 2023138,726$337.1K<0.1%−21,092−13.2%ReducedHolders
Q4 2022159,818$305.3K<0.1%+66,132+70.6%AddedHolders
Q3 202293,686$225.0K<0.1%−118,467−55.8%ReducedHolders
Q2 2022212,153$395.0K<0.1%+870.0%AddedHolders
Q1 2022212,066$443.0K<0.1%+116,066+120.9%AddedHolders
Q4 202196,000$378.0K<0.1%+92,026+2,315.7%AddedHolders
Q3 20213,974$19.0K<0.1%+1,983+99.6%AddedHolders
Q2 20211,991$9.00K<0.1%−11,657−85.4%ReducedHolders
Q1 202113,648$80.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.